NeuroMetrix (NURO) Tops Q3 EPS by 6c

October 20, 2016 7:09 AM EDT
Get Alerts NURO Hot Sheet
Trade NURO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

NeuroMetrix (NASDAQ: NURO) reported Q3 EPS of ($0.76), $0.06 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $3.39 million versus the consensus estimate of $3.01 million.

Recent Highlights:

  • Quell shipments totaled 12,086 devices and 14,391 electrode reorder packages with a total invoiced value of $2.90 million in Q3 2016. This was an increase from 11,201 devices and 10,237 electrode reorder packages with a total invoiced value of $2.53 million in Q2 2016.
  • The Company announced that a clinical study by Brigham and Women’s Hospital in Boston will assess the utility of Quell technology in patients with chronic low back pain.
  • DPNCheck shipments in Q3 2016 reached a 4 year high of 57,400 biosensors, up 45% from 39,500 biosensors in Q3 2015.
  • Final DPNCheck regulatory approval was obtained from the China Food and Drug Administration.
  • A patent was issued in China for the core DPNCheck technology.

For earnings history and earnings-related data on NeuroMetrix (NURO) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment